Fiche du document
16 juin 2017
- doi: 10.1016/j.omtm.2017.05.001
- issn: 2329-0501
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/doi/10.1016/j.omtm.2017.05.001
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pmid/28603746
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pissn/2329-0501
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_A7D9E5D60F014
info:eu-repo/semantics/openAccess , Copying allowed only for non-profit organizations , https://serval.unil.ch/disclaimer
Sujets proches
Genes--Expression Expressive behavior Pattern Model AssessmentCiter ce document
K. Cambon et al., « Preclinical Evaluation of a Lentiviral Vector for Huntingtin Silencing. », Serveur académique Lausannois, ID : 10.1016/j.omtm.2017.05.001
Métriques
Partage / Export
Résumé
Huntington's disease (HD) is an autosomal dominant neurodegenerative disorder resulting from a polyglutamine expansion in the huntingtin (HTT) protein. There is currently no cure for this disease, but recent studies suggest that RNAi to downregulate the expression of both normal and mutant HTT is a promising therapeutic approach. We previously developed a small hairpin RNA (shRNA), vectorized in an HIV-1-derived lentiviral vector (LV), that reduced pathology in an HD rodent model. Here, we modified this vector for preclinical development by using a tat-independent third-generation LV (pCCL) backbone and removing the original reporter genes. We demonstrate that this novel vector efficiently downregulated HTT expression in vitro in striatal neurons derived from induced pluripotent stem cells (iPSCs) of HD patients. It reduced two major pathological HD hallmarks while triggering a minimal inflammatory response, up to 6 weeks after injection, when administered by stereotaxic surgery in the striatum of an in vivo rodent HD model. Further assessment of this shRNA vector in vitro showed proper processing by the endogenous silencing machinery, and we analyzed gene expression changes to identify potential off-targets. These preclinical data suggest that this new shRNA vector fulfills primary biosafety and efficiency requirements for further development in the clinic as a cure for HD.